Teva's EMA application for olanzapine LAI accepted
The long-acting injectable aims to improve adherence and is administered every four weeks.
See the latest news and media coverage for Teva. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company
tevapharm.comLast updated
In short: Teva Pharmaceutical achieved several financial growth milestones, secured multiple biosimilar approvals, and pursued a strategy of targeted acquisitions.
The long-acting injectable aims to improve adherence and is administered every four weeks.
Fitch raised Teva's corporate credit rating to BBB- with stable outlook, reflecting strong financial progress.
The company met all sustainability-linked bond targets, reduced GHG emissions by 39%, and expanded patient access to nearly 8 million people through product donations.
The deal includes ecopipam, a first-in-class therapy for Tourette syndrome, with NDA submission expected in 2H 2026.
They combine active pharmaceutical ... or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology...
Teva Pharmaceutical reported strong Q1 2026 results on April 29, beating EPS expectations at $0.53 versus estimates, driven by CNS portfolio sales up to $837...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Teva competes with other large generics companies and with originator pharmaceutical players that aim to defend their franchises through patent strategies and incremental innovation. The...
Track Teva and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Teva and other trending companies.